Pharma RSS Digest - 2026-04-25
Overview
The April 25, 2026 digest is notably light, with only two developments reaching key-development status. The most pressing item is an FDA early alert involving Arrow International's urgent recall of hemodialysis catheter kits due to a design defect in Merit Medical's splittable sheath introducer that has already caused two serious injuries. Meanwhile, Berlin Heals presented positive first-in-human data for a less invasive cardiac microcurrent device implantation at the Heart Rhythm Society Annual Congress, offering a potential new therapeutic approach for heart failure patients. The contrast between a safety recall and an early-stage innovation highlight underscores the range of risk profiles present in the medtech space on any given day.
Key Developments
FDA Issues Early Alert for Arrow International Hemodialysis Catheter Kit Recall
The FDA posted an early alert on MedWatch regarding Arrow International's urgent recall of dialysis catheter kits containing Merit Medical's 16F Dual-Valved Splittable Sheath Introducer. The defect can cause the sheath to fail to split as designed, potentially leading to hemorrhage, foreign bodies, procedure delays, embolization or thrombosis, impaired catheter function, and loss of vessel access. Merit Medical reported two serious injuries and no deaths as of February 23, 2026, and Arrow International's April customer letter urges immediate cessation of use and return of affected kits. The recall impacts multiple hemodialysis catheter product lines including Arrow Edge, Arrow-Clark VectorFlow, Cannon II Plus, and NextStep. The FDA is reviewing the issue as a high-risk device matter and will update the public as new information becomes available. Providers handling related inquiries should contact Teleflex customer service at 1-866-396-2111. What to watch next: whether FDA escalates this to a Class I recall, whether additional injuries emerge as unused kits are returned, and what remediation steps Arrow International and Merit Medical implement. Source
Berlin Heals Reports Positive Outpatient Implantation Data for Cardiac Microcurrent Device
Berlin Heals Holding AG announced positive results from the CMIC-III First-In-Human study evaluating a less invasive, outpatient approach to implanting their cardiac microcurrent (CMIC) device for heart failure treatment, with Dr. Marat Fudim of Duke University presenting findings at the Heart Rhythm Society Annual Congress in Chicago on April 24, 2026. The procedure demonstrated clinically significant improvements in LVEF, 6MWT, quality of life, and NYHA class consistent with prior surgical implantation data. Across three studies, 52 patients have been implanted with a strong safety profile reported. The company is launching Phase II of CMIC-III to evaluate patients with LVEF greater than 40% to less than 50%, and announced the upcoming C-MIC-IV double-blind sham-controlled trial for patients with LVEF 20-40% primarily in Western European centers. Berlin Heals, a Swiss clinical-stage medtech company founded in 2014, recently raised over $10 million USD to support expansion of this approach. What to watch next: whether the less invasive approach can replicate surgical outcomes across larger and more diverse patient populations, and how enrollment in the upcoming ~122-patient trials proceeds. Source